CD300a Activity Modulator for Inflammatory Disease Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective regulation of the innate immune response via CD300a's inhibitory signal transduction, and there is a need for treatments or preventive measures for diseases associated with excessive inflammatory reactions, such as inflammatory infections, allergic diseases, and autoimmune diseases.
Innovation Solution
Identification of phosphatidyl serine as the ligand for CD300a, with substances like MFG-E8 and anti-CD300a antibodies used to inhibit or promote binding to phosphatidyl serine, thereby modulating CD300a's activity in myeloid cells to suppress or enhance inhibitory signal transduction.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If anti-inflammatory agents are administered to suppress excessive immune function, then inflammatory symptoms are ameliorated, but immune defense capability against pathogens is reduced
Solution Approach 1:
The patent applies local quality by selectively modulating CD300a signaling in specific cell types (myeloid cells) rather than globally suppressing all immune functions. The activity modulator specifically targets CD300a-expressing cells to control inflammation while preserving immune defense in other cell populations, thereby resolving the contradiction between reducing inflammatory symptoms and maintaining immune defense capability
Solution Approach 2:
The patent inverts the conventional approach by instead of suppressing CD300a activity to reduce inflammation, it promotes CD300a activity through activity modulators to achieve anti-inflammatory effects. This inversion reveals that enhancing the inhibitory receptor's function can suppress inflammation without broadly compromising immune defense, thus resolving the technical contradiction
2Reliability
If immunostimulants are administered to eliminate pathogens, then immune function is enhanced, but excessive inflammatory reactions occur
Solution Approach 1:
The patent applies feedback control by utilizing CD300a, an inhibitory receptor that provides negative feedback to regulate immune responses. The activity modulator enhances this feedback mechanism, allowing the immune system to eliminate pathogens effectively while automatically limiting excessive inflammatory reactions through CD300a-mediated inhibition, thus resolving the contradiction between pathogen elimination and inflammatory control
Solution Approach 2:
The patent changes the functional parameter of CD300a from a dormant or insufficiently active state to an optimally active state through activity modulators. This parameter change enhances the receptor's ability to suppress excessive inflammation while maintaining its role in pathogen elimination, thereby resolving the technical contradiction
Data Source
AI summary
The present invention aims to provide: an immunostimulant useful for maintaining, enhancing or suppressing an immune function associated with CD300a activation signaling, or an immunomodulator as an immunosuppressant useful for suppressing the immune function; use of a CD300a gene-deficient mouse for pathology analysis and the like; an anti-CD300a antibody; and the like.